

Astellas Announces Personnel Changes

TOKYO, February 5, 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the personnel changes of Corporate Executive as below.

1. Effective April 1, 2019

[New Corporate Executive Vice President]

Name	New Title	Current Title
Naoki Okamura	Corporate Executive Vice President, CStO	CStO

CStO: Chief Strategy Officer

[New Senior Corporate Executive]

Name	Title (effective on April 1, 2019)
Fumiaki Sakurai	CAO & CECO
Yukio Matsui	CCO
Hideki Shima	President, Pharmaceutical Technology

CAO: Chief Administrative Officer

CECO: Chief Ethics & Compliance Officer

CCO: Chief Commercial Officer

[New Corporate Executive]

Name	Title (effective on April 1, 2019)
Yoshiyuki Naoi	General Manager, Osaka Branch, Japan Commercial
Minetake Kitagawa	Senior Vice President, Development Project Management, Development

2. Effective June 18, 2019

[Resignation of Senior Corporate Executive]

Name	Title (effective on April 1, 2019)	Current Title
Mitsunori Matsuda	CEO's office	President, Pharmaceutical Technology
Masatoshi Kuroda	CEO's office	President, Asia & Oceania Business

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, please visit our website at <https://www.astellas.com/en>

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473